Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Brachytherapy has become increasingly and commonly used in the United States to treat breast cancer after a lumpectomy. Although this therapy and the standard treatment, whole breast irradiation,…
NEW YORK (Reuters Health) – The combination of estrogen and raloxifene seems to reduce menopausal symptoms and appears not to increase the risk of endometrial hyperplasia, researchers from…
NEW YORK (Reuters Health) – Getting a second opinion of surgical breast pathology often leads to changes that impact treatment in women with node-negative breast cancer or ductal…
NEW YORK (Reuters Health) – A randomized, multicenter trial has confirmed that myofascial physical therapy is an effective treatment for women with newly symptomatic interstitial cystitis/painful bladder syndrome…
NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in…
NEW YORK (Reuters Health) – Women older than age 30 are no more likely than younger women to develop hypothyroidism in pregnancy, suggest results a study from the…
NEW YORK (Reuters Health) – Adjuvant tamoxifen after surgery and radiation reduces subsequent ipsilateral and contralateral breast cancers in women with estrogen-receptor (ER)-positive ductal carcinoma in situ (DCIS),…
NEW YORK (Reuters Health) – Women with a history of nephrolithiasis have higher fractional calcium absorption, but consuming adequate calcium reduces fractional absorption and may help prevent kidney…
NEW YORK (Reuters Health) – Having weight loss surgery before having a child may be good for the mother but not necessarily the baby, hints research published this…
NEW YORK (Reuters Health) – Adding the multitargeted tyrosine kinase inhibitor sunitinib (Sutent; Pfizer) to docetaxel did not improve clinical outcomes when used in the first-line setting in…
